Key points are not available for this paper at this time.
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
Choudhury et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: